An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung

Sponsor
Regeneron Pharmaceuticals

Protocol Number
R2810-ONC-16113

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209370

To Learn More Call
201-510-0910

Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-